NLRP3 INFLAMASOME INHIBITOR AND ITS USE

CR20260091APending Publication Date: 2026-05-05NEUROCRINE BIOSCIENCES INC
View PDF 0 Cites 0 Cited by

Patent Information

Authority / Receiving Office
CR · CR
Patent Type
Applications
Current Assignee / Owner
NEUROCRINE BIOSCIENCES INC
Filing Date
2024-08-09
Publication Date
2026-05-05

AI Technical Summary

Technical Problem

In the prior art, there are fewer varieties of NLRP3 inflammasome inhibitors, and it is difficult to develop NLRP3 inflammasome inhibitors with higher activity and better drug properties.

Method used

A compound has been developed, with the general formula Y-W-R 3, wherein W is selected from or, R 1 and R 2 are independently selected from a variety of groups, and a 5-12 membered ring A is formed by a specific linkage method, and R 3 is selected from- (CH 2) n-NR 4-Z-(CH 2) m-R 5 or -(CH 2) n-NR 4-Z-CR cR d-R 5, which has high biological activity and inhibits NLRP3 inflammasomes.

Benefits of technology

This compound has high biological activity on NLRP3 inflammasomes and has important clinical development value. It can effectively prevent and treat diseases related to NLRP3. It has stable metabolism, low toxicity, good pharmacokinetic properties and high security.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

This disclosure pertains to the technical field of pharmaceutical products and relates to an NLRP3 inflammasome inhibitor and its use. Specifically, this disclosure relates to a compound represented by the general formula (I), or a deuterated compound thereof, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof. The definition of each group is as defined in the description. Studies demonstrate that the compound represented by the general formula (I), or a deuterated compound thereof, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, possesses relatively high biological activity against an NLRP3 inflammasome and has significant clinical development value for the treatment of NLRP3 YW-R3-related diseases (I).
Need to check novelty before this filing date? Find Prior Art